| Accession |
PRJCA016912 |
| Title |
Brigatinib Versus Alectinib in ALK-Positive Non-Small Cell Lung Cancer With Disease Progression on Crizotinib |
| Relevance |
Medical |
| Data types |
Variation
Genome sequencing
Biomarker Data
|
| Organisms |
Homo sapiens
|
| Description |
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG) Versus Alectinib(ALECENSA) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI) |
| Sample scope |
Multiisolate |
| Release date |
2023-06-01 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Takeda Pharmaceutical (China) Company Limited
|
|
NA
|
|
|
|
| Submitter |
shun
Lu (shunlu_shchest@sina.com)
|
| Organization |
Shanghai Chest Hospital |
| Submission date |
2023-05-11 |
